PRO CON DEBATE | ANTICOAGULATION VERSUS ENDOVASCULAR THERAPY FOR ACUTE PULMONARY EMBOLISM

Monday, March 10, 2025

11:30 AM – 12:00 PM ET

Moderator(s)

Kenneth Rosenfield, MD, MHCDS

section head, vascular medicine and intervention
Massachusetts General Hospital
boston, Massachusetts, United States

Disclosure information not submitted.

Panel Discussant(s)

Mark C. Bates, MD, DSc, FSCAI

Clinical Professor of Medicine and Surgery
CAMC Institute of Academic Medicine and WVU
Charleston, West Virginia, United States

Disclosure(s): Avobis Bio: Board Chair (Ongoing); WL Gore & Associates: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Salary (Ongoing), Stock-privately held company (Ongoing)
Torrey Schmidt, DO

Director, Pulmonary Embolism Interventional Program
UPMC Harrisburg
Enola, Pennsylvania, United States

Disclosure(s): No financial relationships to disclose
SS

Sanjum S. Sethi, MD

NewYork-Presbyterian Columbia University Irving Medical Center

Disclosure information not submitted.

Disclosure(s):

Alexander G. Truesdell, MD: Abiomed: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Getinge: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Shockwave: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Zoll: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Mark C. Bates, MD, DSc, FSCAI: Avobis Bio: Board Chair (Ongoing); WL Gore & Associates: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Salary (Ongoing), Stock-privately held company (Ongoing)

Torrey Schmidt, DO: No financial relationships to disclose